IP Verse

Methods For Treating Myelodysplastic Syndromes And Sideroblastic Anemias - EP3226887

The patent EP3226887 was granted to Acceleron Pharma on Mar 27, 2024. The application was originally filed on Dec 3, 2015 under application number EP15865103A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3226887

ACCELERON PHARMA
Application Number
EP15865103A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Feb 23, 2024
Grant Date
Mar 27, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

WUESTHOFF & WUESTHOFFDec 20, 2024ADMISSIBLE

Patent Citations (77) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0404097
DESCRIPTIONUS2005079574
DESCRIPTIONUS2005119455
DESCRIPTIONUS2005266000
DESCRIPTIONUS2006025576
DESCRIPTIONUS2006148748
DESCRIPTIONUS2007061900
DESCRIPTIONUS2007117126
DESCRIPTIONUS2007160598
DESCRIPTIONUS2007237764
DESCRIPTIONUS2007292936
DESCRIPTIONUS2009002360
DESCRIPTIONUS2010028331
DESCRIPTIONUS4816567
DESCRIPTIONUS5096815
DESCRIPTIONUS5198346
DESCRIPTIONUS5223409
DESCRIPTIONUS5270163
DESCRIPTIONUS5278065
DESCRIPTIONUS5283317
DESCRIPTIONUS5475096
DESCRIPTIONUS5500362
DESCRIPTIONUS5525490
DESCRIPTIONUS5567588
DESCRIPTIONUS5571894
DESCRIPTIONUS5580737
DESCRIPTIONUS5587458
DESCRIPTIONUS5677196
DESCRIPTIONUS5707796
DESCRIPTIONUS5750373
DESCRIPTIONUS5763177
DESCRIPTIONUS5770429
DESCRIPTIONUS5821337
DESCRIPTIONUS5869046
DESCRIPTIONUS5955280
DESCRIPTIONUS5965368
DESCRIPTIONUS6011577
DESCRIPTIONUS6075181
DESCRIPTIONUS6150584
DESCRIPTIONUS6248516
DESCRIPTIONUS6319499
DESCRIPTIONUS6537966
DESCRIPTIONUS6699843
DESCRIPTIONUS6737056
DESCRIPTIONUS6982321
DESCRIPTIONUS7041870
DESCRIPTIONUS7087409
DESCRIPTIONUS7189826
DESCRIPTIONUS7332581
DESCRIPTIONUS7521541
DESCRIPTIONUS7527791
DESCRIPTIONUS7612041
DESCRIPTIONUS7709605
DESCRIPTIONUS7842663
DESCRIPTIONWO0000823
DESCRIPTIONWO0039585
DESCRIPTIONWO0043781
DESCRIPTIONWO2005025601
DESCRIPTIONWO2005100402
DESCRIPTIONWO2006012627
DESCRIPTIONWO2006029879
DESCRIPTIONWO2007053775
DESCRIPTIONWO2008030367
DESCRIPTIONWO2008097541
DESCRIPTIONWO2010019261
DESCRIPTIONWO2013059347
DESCRIPTIONWO9301161
DESCRIPTIONWO9316185
DESCRIPTIONWO9626432
INTERNATIONAL-SEARCH-REPORTWO2008076437
INTERNATIONAL-SEARCH-REPORTWO2011020045
INTERNATIONAL-SEARCH-REPORTWO2013059347
INTERNATIONAL-SEARCH-REPORTWO2014066487
INTERNATIONAL-SEARCH-REPORTWO2015161220
OPPOSITIONWO2016090077
SEARCHWO2013059347
SEARCHWO2015161220

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Alan List, "Chapter 5: Classification of myelodysplastic syndromes", Alan List, Alan List, Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20111102), pages 23 - 33, ISBN 978-1-85873-427-9, XP009560951-
OPPOSITION- List, Alan, "Chapter 4: Clinical assessment and diagnosis", List, Alan, Alan List, Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20100101), pages 17 - 21, ISBN 978-1-85873-427-9, XP009560950-
OPPOSITION- U. Platzbecker, U. Germing, A. Giagounidis, K. Götze, P. Kiewe, K. Mayer, O. Ottmann, M. Radsak, T. Wolff, D. Haase, M. Hankin, D. Wilson, X. Zhang, A. Laadem, M. Sherman, K. Attie, "Abstract S509 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY", Haematologica, (20150601), vol. 100, no. Suppl. 1, ISSN 0390-6078, page 192, XP009558263-
OPPOSITION- Patnaik Mrinal M., Tefferi Ayalew, "Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, US , (20210301), vol. 96, no. 3, doi:10.1002/ajh.26090, ISSN 0361-8609, pages 379 - 394, XP093251265
OPPOSITION- List Alan, "Chapter 1: Introduction to myelodysplastic syndromes", Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20111102), pages 1 - 7, doi:10.1007/978-1-907673-36-8_1, ISBN 978-1-85873-427-9, XP093223997
OPPOSITION- List Alan, "Chapter 2: Etiology and pathophysiology", Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20111102), pages 9 - 10, doi:10.1007/978-1-907673-36-8_2, ISBN 978-1-85873-427-9, XP093223996
OPPOSITION- List Alan, "Chapter 3: Signs and symptoms of myelodysplastic syndromes", Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20111102), pages 11 - 16, doi:10.1007/978-1-907673-36-8_3, ISBN 978-1-85873-427-9, XP093223998
OPPOSITION- ALAN LIST, "Chapter 6: Management of myelodysplastic syndromes", ALAN LIST, Alan List, Clinician’s Manual on Myelodysplastic Syndromes, Springer Healthcare, (20111102), pages 35 - 53, doi:10.1007/978-1-907673-36-8_6, ISBN 978-1-85873-427-9, XP009558262
OPPOSITION- Sylvia S. Bottomley, Mark D. Fleming, "Sideroblastic Anemia Diagnosis and Management", Novel therapies for myelodysplastic syndromes., United States, United States, (20140801), vol. 28, no. 4, doi:10.1016/j.hoc.2014.04.008, ISSN 1558-1977, pages 653 - 670, XP009560855
OPPOSITION- Platzbecker U., K. Attie, D. Wilson, I. Boyd, U. Germing, K. Goetze, A. Giagounidis, P. Kiewe, K. Mayer, O. Ottman, M. Radsak, T. Wolff, M. Sherman, "P-322 A phase 2, ascending dose study of ACE-536 to treat anemia in low/intermediate-1 risk MDS patients: The PACE-MDS study", Poster Presentations - 12th International Symposium on Myelodysplastic Syndromes / Leukemia Research, (20130501), vol. 37, doi:10.1016/S0145-2126(13)70369-2, page S167, XP093251220
OPPOSITION- T Haferlach, Y Nagata, V Grossmann, Y Okuno, U Bacher, G Nagae, S Schnittger, M Sanada, A Kon, T Alpermann, K Yoshida, A Roller, N Nadarajah, Y Shiraishi, Y Shiozawa, K Chiba, H Tanaka, H P Koeffler, H-U Klein, M Dugas, H Aburatani, A Kohlmann, S Miyano, C Haferlach, W Kern, S Ogawa, "Landscape of genetic lesions in 944 patients with myelodysplastic syndromes", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20140201), vol. 28, no. 2, doi:10.1038/leu.2013.336, ISSN 0887-6924, pages 241 - 247, XP055554495
OPPOSITION- E Bulycheva, M Rauner, H Medyouf, I Theurl, M Bornhäuser, L C Hofbauer, U Platzbecker, "Myelodysplasia is in the niche: novel concepts and emerging therapies", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20150201), vol. 29, no. 2, doi:10.1038/leu.2014.325, ISSN 0887-6924, pages 259 - 268, XP055518203
OPPOSITION- E Papaemmanuil, M. Cazzola, J. Boultwood, L. Malcovati, P. Vyas, D. Bowen, A. Pellagatti, J.S. Wainscoat, E. Hellstrom-Lindberg, C. Gambacorti-Passerini, A.L. Godfrey, I. Rapado, A. Cvejic, R. Rance, C. Mcgee, P. Ellis, L.J. Mudie, P.J. Stephens, S. Mclaren, C.E. Massie, P.S. Tarpey, I. Varela, S. Nik-Zainal, H.R. Davies, A. Shlien, D. Jones, K. Raine, J. Hinton, A.P. Butler, J.W. Teague, E.J. Baxter, J. Score, A. Galli, M.G. Della Porta, E. Travaglino, M. Groves, S. Tauro, N.C. Munshi, K.C. Anderson, A. El-Naggar, A. Fischer, V. Mustonen, A.J. Warren, N.C.P. Cross, A.R. Green, P.A. Futreal, M.R. Stratton, And P.J. Campbell For The Chronic Myeloid Disorders Working Group Of The International Cancer Genome Consortium, "Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts", The new england journal of medicine, vol. 365, doi:10.1056/NEJMoa1103283), pages 1384 - 1395, XP055053063
OPPOSITION- Fenaux Pierre, Platzbecker Uwe, Mufti Ghulam J., Garcia-Manero Guillermo, Buckstein Rena, Santini Valeria, Díez-Campelo María, Finelli Carlo, Cazzola Mario, Ilhan Osman, Sekeres Mikkael A., Falantes José F., Arrizabalaga Beatriz, Salvi Flavia, Giai Valentina, Vyas Paresh, Bowen David, Selleslag Dominik, Dezern Amy E., Jurcic Joseph G., Germing Ulrich, Götze Katharina S., Quesnel Bruno, Beyne-Rauzy Odile, Cluzeau Thomas, Voso Maria-Teresa, Mazure Dominiek, Vellenga Edo, Greenberg Peter L., Hellström-Lindberg Eva, Zeidan Amer M., Adès Lionel, Verma Amit, Savona Michael R., Laadem Abderrahmane, Benzohra Aziz, Zhang Jennie, Rampersad Anita, Dunshee Diana R., Linde Peter G., Sherman Matthew L., Komrokji Rami S., List Alan F., "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes", The New England journal of medicine, Massachusetts Medical Society, US, US , (20200109), vol. 382, no. 2, doi:10.1056/NEJMoa1908892, ISSN 0028-4793, pages 140 - 151, XP055939136
OPPOSITION- L. Malcovati, Papaemmanuil E., Bowen D. T., Boultwood J., Della Porta M. G., Pascutto C., Travaglino E., Groves M. J., Godfrey A. L., Ambaglio I., Galli A., Da Via M. C., Conte S., Tauro S., Keenan N., Hyslop A., Hinton J., Mudie L. J., Wainscoat J. S., Futreal P. A., Stratton M. R., Campbell P. J., Hellstrom-Lindberg E., Cazzola M., "Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms", Blood, (20111208), vol. 118, no. 24, doi:10.1182/blood-2011-09-377275, ISSN 00064971, pages 6239 - 6246, XP055065480
OPPOSITION- Platzbecker Uwe; Dunshee Diana; Komrokji Rami S.; Mufti Ghulam J.; Garcia-Manero Guillermo; Buckstein Rena; Santini Valeria; Díez-Campelo María; Sekeres Mikkael A.; See Wendy L.; Tsai Kevin; Risueño Alberto; Ma Jianglin; Schwickart Martin; Rampersad Anita; Zhang Jennie; Laadem Abderrahmane; Menezes Daniel; MacBeth Kyle; Linde Peter G.; Reynolds Joseph G.; List Alan F.; Fenaux Pierre, "Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20191113), vol. 134, doi:10.1182/blood-2019-123655, ISSN 0006-4971, page 2999, XP086667575
OPPOSITION- Platzbecker U et al, "ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study", www.ashpublications.org, Blood, doi:10.1182/blood.V124.21.411.411, www.ashpublications.org, URL: https://ashpublications.org/blood/article/124/21/411/115384/ACE-536-Increases-Hemoglobin-and-Reduces, XP002797776
OPPOSITION- Platzbecker Uwe; Germing Ulrich; Giagounidis Aristoteles; Goetze Katharina; Kiewe Philipp; Mayer Karin; Ottman Oliver; Radsak Markus P.; Wolff Thomas; Haase Detlef; Hankin Monty; Wilson Dawn M.; Laadem Adberrahmane; Sherman Matthew L.; Attie Kenneth M., "ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20141114), vol. 124, no. 21, doi:10.1182/blood.V124.21.411.411, ISSN 0006-4971, page 411, XP086742362
OPPOSITION- Bejar Rafael, Stevenson Kristen E., Caughey Bennett A., Abdel-Wahab Omar, Steensma David P., Galili Naomi, Raza Azra, Kantarjian Hagop, Levine Ross L., Neuberg Donna, Garcia-Manero Guillermo, Ebert Benjamin L., "Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes", Journal of Clinical Oncology, Grune & Stratton, (20120920), vol. 30, no. 27, doi:10.1200/JCO.2011.40.7379, ISSN 0732-183X, pages 3376 - 3382, XP093251263
SEARCH- BEJAR RAFAEL ET AL, "969: Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples", vol. 118, no. 21, ISSN 0006-4971, (20111118), page 443, BLOOD; 53RD ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH), AMERICAN SOCIETY OF HEMATOLOGY, US; SAN DIEGO, CA, USA, URL: http://www.bloodjournal.org/content/118/21/969, (20180613), XP009506025 [Y] 15 * the whole document *-
SEARCH- L. MALCOVATI ET AL, "Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms", BLOOD, (20111012), vol. 118, no. 24, doi:10.1182/blood-2011-09-377275, ISSN 0006-4971, pages 6239 - 6246, XP055065480 [Y] 15 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents